Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencingInvivoscribe Marketing2022-09-07T22:31:04-07:00June 24th, 2021|Read more
Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphomawmm2023-01-10T16:48:18-08:00April 28th, 2021|Read more
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation SequencingInvivoscribe Marketing2021-04-27T17:17:21-07:00April 20th, 2021|Read more
Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancersInvivoscribe Marketing2021-02-11T19:51:54-08:00November 25th, 2020|Read more
Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten statusInvivoscribe Marketing2021-02-11T19:57:34-08:00November 22nd, 2020|Read more
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2021-11-14T22:08:08-08:00December 5th, 2019|Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTAInvivoscribe Marketing2021-02-26T19:10:37-08:00June 19th, 2019|Read more
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic MalignanciesInvivoscribe Marketing2021-02-26T19:10:45-08:00May 21st, 2019|Read more
Invivoscribe To Present At Biotech Showcase™ 2019 In San Franciscowmm2021-02-26T19:10:54-08:00January 3rd, 2019|Read more
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the USInvivoscribe also Receives National Reimbursement for CDx Assay in JapanInvivoscribe Marketing2021-02-26T19:11:02-08:00November 29th, 2018|Read more
CMA Leukemia and Lymphoma Conference 2024May 17-18, 2024 Shanghai, China On-site Booth https://llc2023.sciconf.cn/cn/web/index/17504
JAMT Congress 2024May 11-12, 2024 Kanazawa, Japan On-site Booth https://convention.jtbcom.co.jp/73jamt/en/index.html